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Abstract
Object To determine whether apparent diffusion coefficient
(ADC) measurements allow discrimination of normal lymph
nodes from lymphomatous lymph nodes, and indolent lym-
phomas from aggressive lymphomas in patients with non-
Hodgkin lymphoma (NHL).
Materials and methods Eighteen healthy volunteers and
thirty-two patients with newly diagnosed NHL (indolent:
n = 16; aggressive: n = 16) underwent diffusion-weighted
imaging. ADCs of normal lymph nodes were compared to
those of lymphomatous lymph nodes, and ADCs of indolent
lymphomas were compared to those of aggressive lympho-
mas. Receiver operating characteristic (ROC) analysis was
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performed when ADCs were significantly different between
two of the aforementioned groups.
Results ADCs (in 10−3 mm2/s) of lymphomatous lymph
nodes (0.70 ± 0.22) were significantly lower (P < 0.0001)
than those of normal lymph nodes (1.00 ± 0.15). Area under
the ROC curve was 0.865. Sensitivity and specificity were
78.1 and 100% when using an optimal cutoff ADC value
of 0.80. On the other hand, ADCs of indolent lymphomas
(0.67 ± 0.21) were not significantly different (P = 0.2997)
from those of aggressive lymphomas (0.74 ± 0.23).
Conclusion ADC measurements show promise as a highly
specific tool for the discrimination of normal lymph nodes
from lymphomatous lymph nodes, but appear to be of no util-
ity in differentiating indolent from aggressive lymphomas.
Keywords Diffusion-weighted magnetic resonance
imaging · Apparent diffusion coefficient · Non-Hodgkin
lymphoma
Introduction
Non-Hodgkin lymphomas (NHLs) comprise approximately
4–5% of all malignancies and are the fourth to fifth most fre-
quently occurring type of cancer in the Western world [1]. In
2009, an estimated 65,980 new cases of NHL will be diag-
nosed in the United States [1]. Once a NHL has been diag-
nosed histologically, extent of disease has to be assessed,
because this determines prognosis and treatment planning
[2,3]. Recently, whole-body diffusion-weighted magnetic
resonance (MR) imaging (DWI) was introduced as a new
imaging modality for staging malignant lymphoma [4–6].
Both normal and lymphomatous lymph nodes exhibit high
signal intensity at DWI [4–6]. Therefore, detection of lym-
phomatous lymph nodes at DWI still depends on size criteria
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that are regarded as imperfect [7]. On the other hand, DWI
allows quantifying diffusion in lymph nodes by means of
apparent diffusion coefficient (ADC) measurements, and
this may aid in the characterization of lymph nodes. It is
expected that malignant tissue, including metastatic lymph
nodes, generally exhibits hypercellularity, increased nucleus-
to-cytoplasm ratios, and an increased amount of macromo-
lecular proteins [8], resulting in a decreased diffusion in
the extra- and intracellular compartments (i.e. lower ADC)
compared to normal lymph nodes [9]. Previous studies [10–
15] have shown that ADCs of lymphomatous lymph nodes
are generally lower than those of metastatic lymph nodes
and benign lymphadenopathy. However, these studies [10–
15] exclusively investigated pathologic lymph nodes with
different histologies and did not compare ADCs of lympho-
matous lymph nodes to those of normal lymph nodes. Fur-
thermore, although some studies [16–21] have shown that
ADCs of metastatic lymph nodes are significantly different
from those of normal lymph nodes, these studies did not
include lymphomatous lymph nodes. Moreover, results of
different studies are generally not comparable due to the use
of different b-values, a different number of b-values, and
different ADC measurement methods. Therefore, it is still
unknown whether ADC measurements can be used for dis-
criminating normal lymph nodes from lymphomatous lymph
nodes in the staging workup of patients with NHL.
Many subtypes of NHLs exist, but they can grossly be
divided into a group of indolent lymphomas and a group
of aggressive lymphomas [2,3,22]. Indolent lymphomas are
characterized by slow growth and are generally considered
incurable, although median survival is relatively long. On
the other hand, aggressive lymphomas are characterized by
rapid growth and can be treated curatively with relatively
high survival rates [2,3]. If transformation from indolent to
aggressive lymphoma (which eventually occurs in 40% of
patients with an indolent lymphoma [2,3]) is clinically sus-
pected, a biopsy should be performed for histologic confir-
mation. However, the lymphomatous site that contains the
tumor cells with the highest malignancy grade can be missed
by biopsy, as a result of which multiple or repeated biop-
sies may sometimes be needed. If DWI can predict which
lymphomatous lesions contain the tumor cells with the high-
est malignancy grade, the number of biopsies and associated
patient morbidity can be reduced. It can be hypothesized
that differences in (sub)cellular structures between indolent
and aggressive lymphomas may lead to different degrees of
diffusivity. For example, grade I and II follicular lympho-
mas, which are the most common of the indolent lymphomas,
consist of small- to intermediate-sized neoplastic cells that
are closely packed [8], thus having a high cellular density.
On the other hand, diffuse large B-cell lymphomas (which
are the most common of the high-grade lymphomas) con-
sist of larger neoplastic cells [8], which may correspond to a
relatively lower cellular density. Since lesions with a higher
cellularity are known to have a lower diffusivity than lesions
with a lower cellularity [23–25], ADC measurements may
also be of utility in predicting malignancy grade in patients
with lymphoma.
The purposes of this study were to investigate whether
ADC measurements allow discrimination of normal lymph
nodes from lymphomatous lymph nodes, and indolent from
aggressive lymphomas in patients with NHL.
Materials and methods
Study participants
This study was approved by the institutional review board
of the University Medical Center Utrecht. All participants
were enrolled after they had been properly informed and
provided written informed consent. Eighteen healthy adult
volunteers (9 men and 9 women; mean age, 22.9 years; age
range, 19–37 years) were prospectively included, in order to
determine ADCs of normal lymph nodes. Exclusion criteria
for this volunteer study were previous surgery or malignancy,
chronic or acute inflammation or infection, and current use
of medicine. Furthermore, twenty-two consecutive patients
with newly diagnosed NHL (21 men and 11 women; median
age, 61.5 years; age range, 22–75 years; 16 indolent lympho-
mas, 16 aggressive lymphomas) were prospectively included,
in order to determine ADCs of lymphomatous lymph nodes.
All patients had undergone at least one excisional biopsy to
histologically confirm the diagnosis of NHL. Biopsies had
been examined by board-certified pathologists with exper-
tise in lymphoma diagnosis, and NHLs had been classified as
indolent or aggressive according to the recent WHO classifi-
cation [22]. Characteristics of included patients are displayed
in Table 1.
MR imaging
MR imaging was performed using a 1.5-T system (Achi-
eva, Philips Healthcare, Best, The Netherlands) with a
4-element phased-array surface coil for signal reception in
all body regions. In the volunteers, axial diffusion-weighted
images of the head/neck and pelvis were acquired. In the
patients, axial diffusion-weighted images of the head/neck,
chest, abdomen, and pelvis were obtained. Note that DWI of
the chest and abdomen was not acquired in the volunteers,
because, in our experience, normal lymph nodes in these
regions are usually not depicted at DWI. Applied sequence
parameters for DWI were as follows: single-shot spin-echo
echo-planar imaging, repetition time/echo time/inversion
time of 8,612/78/180 ms, slice thickness/gap of 4/0 mm,
number of slices of 60, field of view of 450 × 360 mm2,
123
Magn Reson Mater Phy (2011) 24:1–8 3
Table 1 Patient characteristics
No. Age (years) Gender (M/F) Lymphoma classification Indolent/aggressive
1 29 M Diffuse large B-cell lymphoma Aggressive
2 67 M Follicular lymphoma grade I-II Indolent
3 60 M Diffuse large B-cell lymphoma Aggressive
4 61 F Diffuse large B-cell lymphoma Aggressive
5 44 F Diffuse large B-cell lymphoma Aggressive
6 64 F Diffuse large B-cell lymphoma Aggressive
7 58 M Diffuse large B-cell lymphoma Aggressive
8 62 F Diffuse large B-cell lymphoma Aggressive
9 56 M Small lymphocytic lymphoma Indolent
10 66 F Follicular lymphoma grade I-II Indolent
11 62 M Diffuse large B-cell lymphoma Aggressive
12 22 M Anaplastic large cell lymphoma Aggressive
13 59 M Diffuse large B-cell lymphoma Aggressive
14 74 M Diffuse large B-cell lymphoma Aggressive
15 47 M Diffuse large B-cell lymphoma Aggressive
16 58 M Nodal marginal zone lymphoma Indolent
17 47 M Follicular lymphoma Indolent
18 71 F Lymphoplasmacytic lymphoma Indolent
19 72 F Nodal marginal zone lymphoma Indolent
20 55 M Follicular lymphoma grade I-II Indolent
21 60 F Diffuse large B-cell lymphoma Aggressive
22 64 M Follicular lymphoma grade I-II Indolent
23 62 F Extranodal marginal zone lymphoma Indolent
24 68 M Low-grade B-cell lymphoma Indolent
25 75 M Diffuse large B-cell lymphoma Aggressive
26 54 M Follicular lymphoma grade I-II Indolent
27 47 M Diffuse large B-cell lymphoma Aggressive
28 71 M Follicular lymphoma grade I-II Indolent
29 72 F Follicular lymphoma grade I-II Indolent
30 54 M Extranodal marginal zone lymphoma Indolent
31 72 F Angioimmunoblastic T-cell lymphoma Aggressive
32 67 M Follicular lymphoma grade I-II Indolent
acquisition matrix of 128 × 81, motion-probing gradients
in three orthogonal axes, b-values of 0 and 1,000 s/mm2,
number of signal averages of 3, half scan factor of 0.651, par-
allel imaging (SENSitivity Encoding) factor of 2, echo train
length of 43, acquired voxel size of 3.52 × 4.50 × 4.00 mm3,
reconstructed voxel size of 1.76 × 1.76 × 4.00 mm3, image
acquisition under free breathing, and scan time of 4 min
and 4 s for each of the four stations. Of note, at a high
b-value of 1,000 s/mm2, ADC measurements are relatively
perfusion insensitive and theoretically more reflective of tis-
sue cellularity and the integrity of cellular membranes [9].
Furthermore, a b-value of 1,000 s/mm2 yields good back-
ground body signal suppression while highlighting lym-
phomatous lesions [4–6]. Axial trace ADC maps were
created by signals obtained from images with the two
b-values (0 and 1, 000 s/mm2). In all patients, axial CT
images of the neck, chest, abdomen, and pelvis, and coronal
T1-weighted and short inversion time inversion recovery
(STIR) whole-body MR images were acquired in addition
to axial DWI.
Image analysis
All MR images were transferred to a workstation (View-
Forum; Philips Healthcare, Best, The Netherlands). One
observer R.A.J.N., with fourteen years of experience in
MR imaging), reviewed the images of the volunteers, and
another observer T.C.K., with more than two years of
experience in DWI), reviewed the images of the patients.
Both observers knew that they were evaluating scans from
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either healthy subjects or patients with NHL. However, each
observer was blinded to the results of the other observer.
Furthermore, the second observer was blinded to the
lymphoma type of the patients, other clinical and imaging
information, and follow-up findings. In the volunteers, the
largest normal lymph node was identified, and a region of
interest (ROI) was placed in this lymph node on the image
that was obtained at a b-value of 1,000 s/mm2. This ROI
was placed on the slice containing the largest portion of the
lymph node, in order to minimize partial volume averaging
effects. Each ROI was variable so that it included as much
of the nodal parenchyma as possible, but edges of the lymph
node were not included. Accurate localization of the ROI was
checked on the image obtained at a b-value of 0 s/mm2. The
ROI was then copied and pasted onto the ADC map, and the
mean ADC of the lymph node was automatically calculated.
In the patients, lymph nodes were considered lymphomatous
in case their short-axis diameter clearly exceeded 10 mm on
CT, T1-weighted, and STIR whole-body MR images, as is
common in the evaluation of malignant lymphoma [26]. Fur-
thermore, the lymph nodes with a short-axis diameter larger
than 10 mm also had to be positive at pretherapy 18F-fluoro-2-
deoxy-d-glucose positron emission tomography (FDG-PET)
or decrease in size on follow-up CT studies after therapy
(minimum follow-up time of 6 months) if pretherapy FDG-
PET was not performed. Decrease in size on follow-up CT
studies was defined as an at least 50% decrease in the sum
of the product of the perpendicular diameters of the involved
lymph node from baseline (Fig. 1), which is partly in line with
the recently revised response criteria for lymphoma [27]. In
each patient, the largest lymphomatous lymph node was iden-
tified on the CT, T1-weighted, and STIR whole-body MR
Fig. 1 Baseline (pretherapy) CT (a) and 6-month posttherapy CT (b)
in a 54-year-old man with follicular lymphoma. Baseline CT (a) shows
a pathologically enlarged right axillary lymph node (3.5 cm × 3.5 cm)
(arrow) that was selected for ADC analysis. At 6-month posttherapy CT
(b), only small axillary lymph nodes with perpendicular diameters less
than 1.0 cm are visible (arrow), which confirms that the right axillary
lymph node at baseline CT was indeed lymphomatous
Fig. 2 Example of an ADC measurement of a lymphomatous cervi-
cal lymph node in a 60-year-old woman with diffuse large B-cell lym-
phoma. A freehand ROI was placed in the lymphomatous cervical lymph
node, on the image obtained at a b-value of 1,000 s/mm2 (a). The ROI
was then copied and pasted onto the ADC map (b), and the ADC of the
lymphomatous lesion (in this case 0.74 × 10−3 mm2/s) was automati-
cally calculated
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Fig. 3 Example of an ADC measurement of a lymphomatous para-
aortic lymph node in a 72-year-old woman with nodal marginal zone
lymphoma. A freehand ROI was placed in the lymphomatous para-aor-
tic lymph node, on the image obtained at a b-value of 1,000 s/mm2 (a).
The ROI was then copied and pasted onto the ADC map (b), and the
ADC of the lymphomatous lesion (in this case 0.51×10−3 mm2/s) was
automatically calculated
images, and its ADC was measured as described previously.
When lymph nodes showed heterogeneous signal intensity on
native (b = 1,000 s/mm2) diffusion-weighted images, only
the solid-appearing portions (i.e. high signal intensity) were
included in the ROI, while obvious necrotic components (i.e.
low signal intensity) were excluded from the ROI. Of note,
only the largest lymph node in each healthy volunteer and
the largest lymphomatous lymph node in each patient were
analyzed in order to avoid selection and clustering bias [28].
Selecting the largest lymph node in both populations also
reduced inaccuracies in ADC measurements due to partial
volume effects. Representative examples of ADC measure-
ments are shown in Figs. 2 and 3.
Statistical analysis
Kolmogorov–Smirnov tests were used to check whether
ADCs of the different groups were normally distributed.
ADCs of normal lymph nodes were compared to those of
lymphomatous lymph nodes, and ADCs of indolent lym-
phomas were compared to those of aggressive lymphomas,
using unpaired two-tailed t tests. In case the unpaired t tests
revealed a significant difference in ADCs between two of the
aforementioned groups, additional receiver operating charac-
teristic (ROC) analysis was performed to determine the area
under the ROC curve and the optimal cutoff ADC value with
corresponding sensitivity and specificity. P values less than
0.05 were considered to indicate a statistically significant dif-
ference. Statistical analyses were executed using MedCalc
version 10.4.5.0 software (MedCalc, Mariakerke, Belgium).
Results
All diffusion-weighted images were of diagnostic quality,
without any disturbing (susceptibility or motion) artifacts
Fig. 4 Box-and-whisker plots show median (middle line of box), quar-
tiles (top and bottom lines of box), upper extreme value (upper whisker),
lower extreme value (lower whisker), and outliers (circles) for ADCs
(in 10−3 mm2/s) according to nodal status (normal vs. lymphomatous).
ADCs of lymphomatous lymph nodes (mean±SD, 0.70 ± 0.22) were
significantly lower (P ≤ 0.0001) than those of normal lymph nodes
(mean±SD, 1.00 ± 0.15)
(Figs. 2, 3). ROIs for ADC measurements of normal lymph
nodes in the volunteers were placed in left cervical (n = 6),
right cervical (n = 6), right axillary (n = 1), left inguinal
(n = 1), and right inguinal (n = 4) lymph nodes. Mean size
of ROIs in the volunteers was 56 mm2 (standard deviation,
19 mm2; range, 28-87 mm2). ROIs for ADC measurements
of lymphomatous lymph nodes in the patients were placed
in left cervical (n = 4), right cervical (n = 2), left axillary
(n = 4), right axillary (n = 6), para-aortic (n = 8), mesenteric
(n = 2), left perirenal (n = 1), left inguinal (n = 2), and right
inguinal (n = 3) lymph nodes. Lymphomatous involvement
of these lymph nodes was confirmed by pretherapy FDG-PET
in 18 patients and by follow-up CT studies in 14 patients.
Mean size of ROIs in the patients was 908 mm2 (standard
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deviation, 1, 144 mm2; range, 120–4,134 mm2). Kolmogo-
rov–Smirnov tests confirmed that the ADCs of the different
groups were normally distributed, justifying comparisons by
means of unpaired t tests.
ADCs (in 10−3 mm2/s) of lymphomatous lymph nodes
(mean ± SD, 0.70 ± 0.22) were significantly lower (P <
0.0001) than those of normal lymph nodes (mean ± SD,
1.00 ± 0.15). Box-and-whisker plots with ADCs accord-
ing to nodal status (normal vs. lymphomatous) are shown
in Fig. 4. Area under the ROC curve was 0.865 (95% CI:
0.738–0.945). The ROC curve is displayed in Fig. 5. Sensi-
tivity was 78.1% (95% CI: 60.0–90.7%) and specificity was
Fig. 5 ROC curve for ADC measurements for the determination of
nodal status (normal vs. lymphomatous). Area under the ROC curve
was 0.865 (95% CI 0.738–0.945)
Fig. 6 Box-and-whisker plots show median (middle line of box), quar-
tiles (top and bottom lines of box), upper extreme value (upper whisker),
lower extreme value (lower whisker), and outliers (circles) for ADCs
(in 10−3 mm2/s) according to lymphoma type (indolent vs. aggressive).
ADCs of indolent lymphomas (mean ± SD, 0.67 ± 0.21) were not sig-
nificantly different (P = 0.2997) from those of aggressive lymphomas
(mean±SD, 0.74 ± 0.23)
100% (95% CI: 81.5–100%) when using an optimal cutoff
ADC value of 0.80.
ADCs of indolent lymphomas (mean±SD, 0.67 ± 0.21)
were not significantly different (P = 0.3691) from those of
aggressive lymphomas (mean±SD, 0.74 ± 0.23). Box-and-
whisker plots with ADCs according to lymphoma type (indo-
lent vs. aggressive) are shown in Fig. 6.
Discussion
Accurate assessment of spread of nodal disease in patients
with NHL is important for determining prognosis and treat-
ment planning [2,3]. The relatively recent development of
whole-body DWI [29,30] made it a feasible technique for
staging NHL [4–6]. DWI not only allows visualizing ana-
tomic abnormalities, but it also provides functional informa-
tion in that it allows quantification of the random motion of
water molecules (i.e. diffusion) by means of ADC measure-
ments [31]. The ADC may provide a reflection of anatomic
and functional cellular characteristics. For example, the ADC
has shown to be inversely correlated to the tissue cellular-
ity and the integrity of cell membranes [23–25]. As such, it
may aid in the characterization of lesions [9], including the
assessment of lymph nodes in patients with NHL. Previous
studies in patients presenting with cervical lymphadenopa-
thy have reported ADCs (in 10−3 mm2/s) of lymphomatous
lymph nodes of 0.22 ± 0.056 [10], 0.449 ± 0.096 (without
nodal necrosis) [11], 0.601 ± 0.427 [12], 0.64 ± 0.09 [15],
0.664 ± 0.071 [14], 0.97 ± 0.27 [13], and 1.091 ± 0.405
(with nodal necrosis) [11]. Note that reported ADCs of lym-
phomatous lymph nodes vary widely, which can be explained
by different ways of ADC measurements (e.g. measurement
of the entire lymph node will result in a higher ADC than in a
measurement in which necrotic regions are excluded) and the
use of different b-values. Nevertheless, all previous studies
[10–15] reported that ADCs of lymphomatous lymph nodes
are generally lower than those of metastatic lymph nodes and
benign lymphadenopathy. However, the utility of ADC mea-
surements in the assessment of lymph nodes in the staging
workup of patients with NHL was still unknown, because pre-
vious studies only investigated whether ADC measurements
allow histologic differentiation of pathologic lymph nodes
rather than assessing whether they can discriminate normal
from lymphomatous lymph nodes. Interestingly, ADC mea-
surements may also be used as a noninvasive predictor of
malignancy grade. Several studies have shown that ADC
measurements may aid in grading brain tumors [23,24,32–
36], with high-grade brain tumors having a lower ADC than
low-grade brain tumors, probably due to higher cellularity
of the former. However, the value of ADC measurements in
grading NHLs was still unknown.
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In the present study, ADCs (in 10−3 mm2/s) of lympho-
matous lymph nodes in patients with NHL (0.70 ± 0.22)
were significantly lower than those of normal lymph nodes in
healthy volunteers (1.00±0.15). Furthermore, ROC analysis
showed that a sensitivity of 78.1% (95% CI 60.0–90.7%) and
a specificity of 100% (95% CI 81.5–100%) can be achieved
when using an optimal cutoff ADC value of 0.80. This may
suggest that a lymph node with an ADC lower than 0.78 in
a patient with NHL is probably lymphomatous. This find-
ing can be explained by the fact that most lymphoma types
mostly consist of densely packed cellular tissue with very
little extracellular space [8], which considerably impedes the
diffusivity of water molecules. On the other hand, our results
indicate that ADC measurements in DWI do not allow dis-
crimination of indolent from aggressive lymphomas, given
the nonsignificant difference in ADCs between both groups.
A possible explanation for this finding may be that cellular
density of indolent lymphomas is not too different from that
of aggressive lymphomas.
This study had several limitations. First, because of
the insensitivity of size criteria to diagnose lymphomatous
involvement of normal-sized lymph nodes [7] and the practi-
cal and ethical impossibility to obtain additional biopsies in
the patients with NHL, only enlarged lymphomatous lymph
nodes could be evaluated. In addition, a group of healthy
volunteers had to be included to determine the ADC of nor-
mal lymph nodes. Although the volunteers were considerably
younger than the patients, there is no reason to assume why
(ADCs of) lymph nodes in a young population would differ
from those in an older population [8]. Furthermore, the same
imaging protocol and the same ADC measurement method
were applied in both the healthy volunteers and the patients.
Second, the site of ADC measurement did not correspond
to the site of the initial biopsy in any of the patients. This
is because imaging for staging takes place after the diag-
nosis of NHL has been established by means of excisional
biopsy. Obtaining additional biopsies of the lymphomatous
lymph nodes that were used for ADC analysis would be
most desirable, but was simply impossible due to aforemen-
tioned reasons. Nevertheless, accepted diagnostic criteria for
nodal involvement in NHL [26] were used and pretherapy
FDG-PET or follow-up CT studies were reviewed to con-
firm that the lymph nodes of the patients that were analyzed
were indeed lymphomatous. Furthermore, although we can-
not exclude the coexistence of aggressive disease in patients
with newly diagnosed indolent lymphoma, this probability is
very low, because high-grade transformation typically occurs
only months to years after initial diagnosis [37–39]. In addi-
tion, none of the patients with indolent lymphoma had clinical
features (e.g. considerably elevated lactate dehydrogenase
or rapid lymphoma growth) that would suggest high-grade
transformation. Third, lymph nodes in the healthy volunteers
that were selected for ADC measurements did not match to
those of the patients with respect to location and size, but this
limitation was inherent to the chosen study design. Fourth,
the degree of confidence that can be ascribed to measuring
ADCs of normal-sized lymph nodes in healthy volunteers
is uncertain. Fifth, only two b-values (0 and 1,000 s/mm2)
were used for ADC calculation. It may have been desirable
to acquire more b-values in order to obtain more accurate
ADCs [9]. However, this would considerably prolong scan
time. It should also be mentioned that the use of different MR
parameters (in particular the number of b-values) and differ-
ent methods of ROI analysis (e.g. inclusion of necrotic areas)
may have resulted in different ADCs, which limits the gen-
eral applicability of the ADC threshold that was obtained in
the present study. Despite these study limitations, the present
results indicate that ADC measurements may be used as an
additional tool in the assessment of lymph nodes (e.g. in case
of borderline lymph node enlargement at anatomic imaging)
in the staging workup of patients with NHL.
Conclusion
In conclusion, our results suggest that ADC measurements
show promise as a highly specific tool for the discrimination
of normal lymph nodes from lymphomatous lymph nodes in
patients with NHL. However, ADC measurements appear to
be of no utility in differentiating indolent from aggressive
lymphomas.
Acknowledgments This study was supported by ZonMw programme
for Health Care Efficiency Research (grant number 80-82310-98-
08012).
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer
statistics, 2009. CA Cancer J Clin 59:225–249
2. Ansell SM, Armitage J (2005) Non-Hodgkin lymphoma: diagno-
sis and treatment. Mayo Clin Proc 80:1087–1097
3. Evans LS, Hancock BW (2003) Non-Hodgkin lymphoma. Lancet
362:139–146
4. Kwee TC, van Ufford HM, Beek FJ, Takahara T, Uiterwaal CS, Bi-
erings MB, Ludwig I, Fijnheer R, Nievelstein RA (2009) Whole-
body MRI, including diffusion-weighted imaging, for the initial
staging of malignant lymphoma: comparison to computed tomog-
raphy. Invest Radiol 44:683–690
5. Li S, Xue HD, Li J, Sun F, Jiang B, Liu D, Sun HY, Jin
ZY (2008) Application of whole body diffusion weighted MR
imaging for diagnosis and staging of malignant lymphoma. Chin
Med Sci J 23:138–144
6. Lin C, Luciani A, Itti E, El-Gnaoui T, Vignaud A, Beaussart P,
Lin SJ, Belhadj K, Brugières P, Evangelista E, Haioun C, Meignan
M, Rahmouni A (2010) Whole-body diffusion-weighted magnetic
123
8 Magn Reson Mater Phy (2011) 24:1–8
resonance imaging with apparent diffusion coefficient mapping for
staging patients with diffuse large B-cell lymphoma. Eur Radiol
20:2027–2038
7. Torabi M, Aquino SL, Harisinghani MG (2004) Current concepts
in lymph node imaging. J Nucl Med 45:1509–1518
8. Ioachim HL, Medeiros LJ (2008) Ioachim’s lymph node pathol-
ogy. Lippincott Williams and Wilkins, Philadelphia
9. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara
T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud
DA, Rustin GJ, Taouli B, Choyke PL (2009) Diffusion-weighted
magnetic resonance imaging as a cancer biomarker: consensus and
recommendations. Neoplasia 11:102–125
10. Sumi M, Van Cauteren M, Nakamura T (2006) MR microimaging
of benign and malignant nodes in the neck. AJR Am J Roentgenol
186:749–757
11. Sumi M, Nakamura T (2009) Diagnostic importance of focal
defects in the apparent diffusion coefficient-based differentiation
between lymphoma and squamous cell carcinoma nodes in the
neck. Eur Radiol 19:975–981
12. Sumi M, Sakihama N, Sumi T, Morikawa M, Uetani M, Kabasawa
H, Shigeno K, Hayashi K, Takahashi H, Nakamura T (2003) Dis-
crimination of metastatic cervical lymph nodes with diffusion-
weighted MR imaging in patients with head and neck cancer. AJNR
Am J Neuroradiol 24:1627–1634
13. Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK,
Tawfik A (2006) Role of diffusion-weighted MR imaging in cer-
vical lymphadenopathy. Eur Radiol 16:1468–1477
14. King AD, Ahuja AT, Yeung DK, Fong DK, Lee YY, Lei KI,
Tse GM (2007) Malignant cervical lymphadenopathy: diagnostic
accuracy of diffusion-weighted MR imaging. Radiology 245:806–
881
15. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa
J (2009) Value of diffusion-weighted MR imaging in the differen-
tiation between benign and malignant cervical lymph nodes. Eur J
Radiol 72:381–387
16. Kim JK, Kim KA, Park BW, Kim N, Cho KS (2008) Feasibility
of diffusion-weighted imaging in the differentiation of metastatic
from nonmetastatic lymph nodes: early experience. J Magn Reson
Imaging 28:714–719
17. Vandecaveye V, De Keyzer F, Vander Poorten V, Dirix P, Ver-
beken E, Nuyts S, Hermans R (2009) Head and neck squamous
cell carcinoma: value of diffusion-weighted MR imaging for nodal
staging. Radiology 251:134–146
18. Sakurada A, Takahara T, Kwee TC, Yamashita T, Nasu S, Horie T,
Van Cauteren M, Imai Y (2009) Diagnostic performance of diffu-
sion-weighted magnetic resonance imaging in esophageal cancer.
Eur Radiol 19:1461–1469
19. Park SO, Kim JK, Kim KA, Park BW, Kim N, Cho G, Choi HJ, Cho
KS (2009) Relative apparent diffusion coefficient: determination
of reference site and validation of benefit for detecting metastatic
lymph nodes in uterine cervical cancer. J Magn Reson Imaging
29:383–390
20. Yasui O, Sato M, Kamada A (2009) Diffusion-weighted imaging
in the detection of lymph node metastasis in colorectal cancer. To-
hoku J Exp Med 218:177–183
21. de Bondt RB, Hoeberigs MC, Nelemans PJ, Deserno WM, Peutz-
Kootstra C, Kremer B, Beets-Tan RG (2009) Diagnostic accuracy
and additional value of diffusion-weighted imaging for discrimina-
tion of malignant cervical lymph nodes in head and neck squamous
cell carcinoma. Neuroradiology 51:183–192
22. Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele
J, Vardiman JW (2008) WHO classification of tumours of haema-
topoietic and lymphoid tissues, 4th edn. International Agency for
Research on Cancer, Lyon
23. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Kor-
ogi Y, Makino K, Nakamura H, Ikushima I, Yamura M, Kochi
M, Kuratsu JI, Yamashita Y (2006) Diffusion-weighted imaging
of metastatic brain tumors: comparison with histologic type and
tumor cellularity. AJNR Am J Neuroradiol 27:1419–1425
24. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai
T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi
M (1999) Usefulness of diffusion-weighted MRI with echo-planar
technique in the evaluation of cellularity in gliomas. J Magn Reson
Imaging 9:53–60
25. Schnapauff D, Zeile M, Niederhagen MB, Fleige B, Tunn PU,
Hamm B, Dudeck O (2009) Diffusion-weighted echo-planar mag-
netic resonance imaging for the assessment of tumor cellular-
ity in patients with soft-tissue sarcomas. J Magn Reson Imaging
29:1355–1359
26. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl
RL (2005) Direct comparison of FDG PET and CT findings in
patients with lymphoma: initial experience. Radiology 237:1038–
1045
27. Cheson BD, Pfistner B, Juweid ME, International Harmonization
Project on Lymphoma et al (2007) Revised response criteria for
malignant lymphoma. J Clin Oncol 25:579–586
28. Sica GT (2006) Bias in research studies. Radiology 238:780–789
29. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren
M (2004) Diffusion weighted whole body imaging with back-
ground body signal suppression (DWIBS): technical improvement
using free breathing, STIR and high resolution 3D display. Radiat
Med 22:275–282
30. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten
PR (2008) Diffusion-weighted whole-body imaging with back-
ground body signal suppression (DWIBS): features and potential
applications in oncology. Eur Radiol 18:1937–1952
31. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, La-
val-Jeantet M (1988) Separation of diffusion and perfusion in in-
travoxel incoherent motion MR imaging. Radiology 168:497–505
32. Murakami R, Hirai T, Sugahara T, Fukuoka H, Toya R, Nishimura
S, Kitajima M, Okuda T, Nakamura H, Oya N, Kuratsu J, Yamash-
ita Y (2009) Grading astrocytic tumors by using apparent diffusion
coefficient parameters: superiority of a one- versus two-parameter
pilot method. Radiology 251:838–845
33. Arvinda HR, Kesavadas C, Sarma PS, Thomas B, Radhakrishnan
VV, Gupta AK, Kapilamoorthy TR, Nair S (2009) Glioma grad-
ing: sensitivity, specificity, positive and negative predictive values
of diffusion and perfusion imaging. J Neurooncol 94:87–96
34. Lee EJ, Lee SK, Agid R, Bae JM, Keller A, Terbrugge K (2008)
Preoperative grading of presumptive low-grade astrocytomas on
MR imaging: diagnostic value of minimum apparent diffusion
coefficient. AJNR Am J Neuroradiol 29:1872–1877
35. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Ume-
tsu A, Sato A, Yamada T, Takahashi S (2006) Malignant astro-
cytic tumors: clinical importance of apparent diffusion coefficient
in prediction of grade and prognosis. Radiology 241:839–846
36. Bulakbasi N, Guvenc I, Onguru O, Erdogan E, Tayfun C, Ucoz
T (2004) The added value of the apparent diffusion coefficient
calculation to magnetic resonance imaging in the differentiation
and grading of malignant brain tumors. J Comput Assist Tomogr
28:735–746
37. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C,
Bryon PA, Coiffier B (1997) Incidence, predictive factors, and out-
come of lymphoma transformation in follicular lymphoma patients.
J Clin Oncol 15:1587–1594
38. O’Brien ME, Easterbrook P, Powell J, Blackledge GR, Jones L,
MacLennan IC, Leonard RC (1991) The natural history of low
grade non-Hodgkin’s lymphoma and the impact of a no initial treat-
ment policy on survival. Q J Med 80:651–660
39. Horning SJ, Rosenberg SA (1984) The natural history of initially
untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med
311:1471–1475
123
